SCHEMBL1505347

SCHEMBL1505347

CC(C)c1ccc(C(=N)N)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.61
PLAU P00749 2/20 0.58
MASP2 O00187 1/20 0.58
THPO P40225 1/20 0.58
PRSS1 P07477 4/20 0.56
PRSS3 P35030 4/20 0.56
F2 P00734 3/20 0.56
APEX1 P27695 1/20 0.56
LMNA P02545 2/20 0.54
PRSS2 P07478 3/20 0.50
ST14 Q9Y5Y6 1/20 0.48
PRMT5 O14744 1/20 0.48
PRMT1 Q99873 1/20 0.48
ALDH1A1 P00352 1/20 0.48
HPGD P15428 1/20 0.48
CYP2C19 P33261 1/20 0.48
HSD17B10 Q99714 1/20 0.48
F10 P00742 2/20 0.48
F12 P00748 1/20 0.48
F7 P08709 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20878620 0.80 PLAU (0.63) HTTPLAUPRSS1PRSS3F2
SCHEMBL14599535 0.80 F2 (0.76) PRSS1PRSS3F2PRSS2ST14
SCHEMBL537030 0.79 LMNA (0.77) PLAUMASP2THPOPRSS1PRSS3
SCHEMBL23049360 0.79 PRSS1 (0.48) PLAUMASP2THPOPRSS1PRSS3
SCHEMBL12545975 0.78 HTT (0.52) HTTLMNAALDH1A1
SCHEMBL12792667 0.77 CPN1 (0.57) PRSS1PRSS3F2LMNAPRSS2
SCHEMBL1445804 0.77 CPN1 (0.45) PLAUMASP2THPOPRSS1PRSS3
SCHEMBL14132737 0.76 HTT (0.61) HTTPRSS1LMNAALDH1A1NOS3
SCHEMBL84429 0.76 HTT (0.61) HTTPRSS1LMNAALDH1A1CYP2C19
SCHEMBL1505191 0.76 HTT (1.00) HTTPRSS1LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12030853-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2024-07-09 US disclosed
US-11708346-B2 Treatment and prevention of neuropathic pain with P2Y14 antagonists SAINT LOUIS UNIVERSITY (US) 2023-07-25 US disclosed
US-20230174470-A1 COMPOUND AS A UBR BOX DOMAIN LIGAND AUTOTAC INC. (KR) 2023-06-08 US disclosed
US-20230058729-A1 MACROCYCLES AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2023-02-23 US disclosed
US-11584736-B2 Heterocyclic P2Y14 receptor antagonists THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2023-02-21 US disclosed
US-11584714-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2023-02-21 US disclosed
US-20220169676-A1 INHIBITORS OF GROWTH FACTOR ACTIVATION ENZYMES WASHINGTON UNIVERSITY (US) 2022-06-02 US disclosed
US-11136327-B2 Macrocycles as factor XIA inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2021-10-05 US disclosed
US-11130780-B2 Inhibitors of growth factor activation enzymes WASHINGTON UNIVERSITY (US) 2021-09-28 US disclosed
US-20210171461-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION 2021-06-10 US disclosed
WO-2011025565-A1 MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2011-03-03 WO disclosed
US-20090253699-A1 Compounds for Nonsense Suppression, and Methods for Their Use PCT THERAPEUTICS, INC. (US) 2009-10-08 US disclosed
US-20080119473-A1 Compounds for Nonsense Suppression, and Methods for Their Use PTC THERAPEUTICS, INC. 2008-05-22 US disclosed
CN-101076703-A Compounds for nonsense inhibition and methods of use thereof PTC THERAPEUTICS INC (US) 2007-11-21 CN disclosed
CN-101076337-A Compounds for inhibiting nonsense mutations and methods of use thereof PTC THERAPEUTICS INC (US) 2007-11-21 CN disclosed
EP-1815206-A1 COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE PTC Therapeutics, Inc. (US) 2007-08-08 EP disclosed
EP-1799212-A2 COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE PTC Therapeutics, Inc. (US) 2007-06-27 EP disclosed
WO-2007008541-A2 CELLULAR CHOLESTEROL ABSORPTION MODIFIERS KALYPSYS, INC. (US) 2007-01-18 WO disclosed
WO-2006044505-A2 COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE PTC THERAPEUTICS, INC. (US) 2006-04-27 WO disclosed
WO-2006044456-A1 COMPOUNDS FOR NONSENSE SUPPRESSION, AND METHODS FOR THEIR USE PTC THERAPEUTICS, INC. (US) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584714-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 HTT 2394/4885PLAU 301/4885MASP2 1/4885
US-11708346-B2 Treatment and prevention of neuropathic pain with P2Y14 antagonists P2RY14, P2RY4, P2RY13 HTT 2054/4885PLAU 1368/4885MASP2 1640/4885
US-11584736-B2 Heterocyclic P2Y14 receptor antagonists P2RY14, P2RY1, P2RY13 HTT 4417/4885PLAU 1548/4885MASP2 3103/4885
US-20080119473-A1 Compounds for Nonsense Suppression, and Methods for Their Use NSUN2, UPF1, NSUN3 HTT 78/4885PLAU 2958/4885MASP2 3118/4885
US-11136327-B2 Macrocycles as factor XIA inhibitors TFPI, TFPI2, F11 HTT 2077/4885PLAU 31/4885MASP2 162/4885
US-20090253699-A1 Compounds for Nonsense Suppression, and Methods for Their Use NSUN2, UPF1, NSUN3 HTT 78/4885PLAU 2958/4885MASP2 3118/4885
US-11130780-B2 Inhibitors of growth factor activation enzymes HDGF, MMP7, HGF HTT 1900/4885PLAU 46/4885MASP2 128/4885
US-20220169676-A1 INHIBITORS OF GROWTH FACTOR ACTIVATION ENZYMES HDGF, MMP7, HGF HTT 1900/4885PLAU 46/4885MASP2 128/4885
US-20230174470-A1 COMPOUND AS A UBR BOX DOMAIN LIGAND UBR4, UBQLN2, UBTF HTT 258/4885PLAU 3647/4885MASP2 2606/4885
US-20230058729-A1 MACROCYCLES AS FACTOR XIA INHIBITORS TFPI, TFPI2, F11 HTT 2077/4885PLAU 31/4885MASP2 162/4885
US-12030853-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 HTT 2319/4885PLAU 303/4885MASP2 1/4885
US-20210171461-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 HTT 2319/4885PLAU 303/4885MASP2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.